| Issue | Title | |
| Vol 2012, No 1 (2012) | Novartis | Abstract |
| Nigel Borshell | ||
| Vol 2012, No 2 (2012) | Novartis | Abstract |
| Nigel Borshell | ||
| Vol 2012, No 3 (2012) | Novartis | Abstract |
| Nigel Borshell, Taskin Ahmed | ||
| Vol 2012, No 4 (2012) | Novartis | Abstract |
| Heather Cartwright, Taskin Ahmed | ||
| Vol 2013, No 1 (2013) | Novartis | Abstract |
| Heather Cartwright, Taskin Ahmed | ||
| Vol 2011, No 1 (2011) | Pfizer | Abstract |
| Nigel Borshell | ||
| Vol 2011, No 2 (2011) | Pfizer | Abstract |
| Nigel Borshell | ||
| Vol 2011, No 3 (2011) | Pfizer | Abstract |
| Nigel Borshell | ||
| Vol 2011, No 4 (2011) | Pfizer | Abstract |
| Nigel Borshell | ||
| Vol 2011, No 5 (2011) | Pfizer | Abstract |
| Nigel Borshell | ||
| Vol 2011, No 6 (2011) | Pfizer | Abstract |
| Nigel Borshell | ||
| Vol 2012, No 1 (2012) | Pfizer | Abstract |
| Nigel Borshell | ||
| Vol 2012, No 2 (2012) | Pfizer | Abstract |
| Nigel Borshell | ||
| Vol 2012, No 3 (2012) | Pfizer | Abstract |
| Nigel Borshell, Taskin Ahmed | ||
| Vol 2012, No 4 (2012) | Pfizer | Abstract |
| Heather Cartwright, Taskin Ahmed | ||
| Vol 2013, No 1 (2013) | Pfizer | Abstract |
| Heather Cartwright, Taskin Ahmed | ||
| Vol 2011, No 4 (2011) | Pfizer and GSK Swap Places in PharmaDeals Corp-METRx Deal Activity League Table | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 5 (2011) | Pfizer’s Deal Activity Ranking Improves but Roche Still Leads | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 1 (2011) | Roche | Abstract |
| Nigel Borshell | ||
| Vol 2011, No 2 (2011) | Roche | Abstract |
| Nigel Borshell | ||
| Vol 2011, No 3 (2011) | Roche | Abstract |
| Nigel Borshell | ||
| Vol 2011, No 4 (2011) | Roche | Abstract |
| Nigel Borshell | ||
| Vol 2011, No 5 (2011) | Roche | Abstract |
| Nigel Borshell | ||
| Vol 2011, No 6 (2011) | Roche | Abstract |
| Nigel Borshell | ||
| Vol 2012, No 1 (2012) | Roche | Abstract |
| Nigel Borshell | ||
| 101 - 125 of 143 Items | << < 1 2 3 4 5 6 > >> | |